Transition metal complexes and catalysts

Transition metal complexes sit at the intersection of synthetic methodology and pharmaceutical manufacturing, serving as the catalytic engine of the most widely applied bond-forming reactions across the entire drug development pipeline. A recent analysis of pharmaceutical process chemistry reported that over 43% of all syntheses published in Organic Process Research and Development between 2017 and 2021 contained at least one transition-metal-catalysed step, with palladium accounting for approximately 80% of those transformations and ruthenium, copper, iridium, rhodium, nickel, and manganese making up the remainder in decreasing order of frequency. Beyond their dominant synthetic role, transition metal complexes have an established and growing profile as drug substances in their own right: cisplatin, carboplatin, and oxaliplatin, platinum coordination complexes, remain cornerstones of oncology, and a new generation of ruthenium, gold, and copper complexes are advancing through clinical development as next-generation metallodrugs with distinct mechanisms of action from organic small molecules. The design of transition metal complexes as therapeutics exploits the unique reactivity of the metal centre, its Lewis acidity, ligand substitution kinetics, redox activity, and the ability to generate reactive oxygen species, to achieve target engagement modes that are entirely inaccessible to carbon-only pharmacophores. In synthetic applications, the catalyst performance of transition metal complexes is governed by the nature of the metal, its oxidation state, the geometry and electronics of the co-ordinated ligands, and the reaction conditions, and the systematic variation of these parameters through ligand design has been the primary driver of the enormous expansion in cross-coupling scope over the past three decades. Palladium-ligand complexes exhibit a catalytic cycle of oxidative addition, transmetalation, and reductive elimination that is broadly applicable to C-C, C-N, C-O, and C-S bond formation, and the introduction of bulkier, more electron-rich phosphine ligands has extended this reactivity to challenging substrates including sterically hindered aryl chlorides and electron-rich heteroarenes. Nickel complexes, operating through complementary single-electron mechanisms, are gaining significant traction as earth-abundant, cost-effective alternatives to palladium, particularly for alkyl-aryl cross-couplings and reductive coupling reactions that exploit the accessibility of the Ni(0)/Ni(I)/Ni(II)/Ni(III) manifold. The role of transition metal complex catalysis as an enabling technology in pharmaceutical manufacturing is recognised at the highest levels: Knowles, Noyori, and Sharpless shared the 2001 Nobel Prize in Chemistry for asymmetric transition-metal-catalysed reactions that directly transformed pharmaceutical manufacturing, and Suzuki and Heck shared the 2010 Prize for palladium-catalysed cross-coupling that now underpins the synthesis of the majority of approved small-molecule drugs.

Two first-in-class FDA-approved drugs from 2024 illustrate the direct role of transition metal complex catalysis in pharmaceutical synthesis. Vorasidenib (Voranigo, Servier), the first-in-class dual inhibitor of mutant IDH1 and IDH2 approved in August 2024 for the treatment of IDH-mutant grade 2 diffuse glioma, is assembled via a multistep synthesis in which palladium-catalysed cross-coupling reactions are central to constructing the fluorinated triazine-aryl framework that constitutes its pharmacophore, with the palladium complex mediating the key C-C bond formations that establish the biaryl connectivity critical to dual IDH1/2 binding affinity. Resmetirom (Rezdiffra, Madrigal Pharmaceuticals), the first and only FDA-approved treatment for metabolic dysfunction-associated steatohepatitis (MASH) with moderate-to-advanced fibrosis, approved in March 2024, contains a diaryl ether scaffold, a structural motif most efficiently assembled by palladium or copper-catalysed C-O coupling from aryl halide precursors, whose liver-targeted, selective THR-β agonist activity depends critically on the precise positioning of the chlorine and alkyl substituents established during these metal-catalysed bond-forming steps.

In organic synthesis, transition metal complexes underpin a broad range of foundational named reactions that define modern pharmaceutical synthesis. The Suzuki-Miyaura coupling, using palladium with phosphine or NHC ligands, couples arylboronic acids with aryl halides to form biaryl systems and is the most frequently used C-C bond-forming reaction in the pharmaceutical industry. The Buchwald-Hartwig amination and Chan-Lam coupling form C-N bonds between aryl halides and amines under palladium and copper catalysis respectively. The Negishi coupling partners organozinc reagents with aryl halides under palladium, while the Kumada coupling uses Grignard reagents under nickel or palladium. The Heck-Mizoroki reaction forms C-C bonds between aryl halides and alkenes under palladium with retention of the double bond, widely used in pharmaceutical and agrochemical synthesis. The Wacker oxidation converts terminal alkenes to methyl ketones using palladium(II)/copper co-catalysis under aerobic conditions. Ruthenium-BINAP and rhodium-Josiphos complexes enable catalytic asymmetric hydrogenation with the high enantioselectivities and turnover numbers required for industrial API manufacture. The Grubbs ruthenium carbene complexes enable ring-closing and cross-metathesis reactions that give rapid access to strained and macrocyclic drug scaffolds. The Sharpless asymmetric dihydroxylation, using osmium tetroxide with cinchona alkaloid ligands, is a key route to chiral diol-containing intermediates across pharmaceutical synthesis.

Emerging synthetic techniques are substantially advancing the scope of transition metal complex catalysis. In photochemistry, iridium(III) and ruthenium(II) polypyridyl complexes, most prominently Ir[dF(CF3)ppy]2(dtbpy) and Ru(bpy)3Cl2, function as single-electron photoredox catalysts under visible-light irradiation, generating excited states capable of oxidising or reducing organic substrates to initiate radical intermediates. When coupled with nickel or palladium in dual metallaphotoredox systems, these iridium photocatalysts enable C(sp3)-C(sp2) and C(sp3)-heteroatom cross-couplings from abundant, simple radical precursors, including carboxylic acids, amines, and alkyl halides, under mild conditions that are unattainable by classical two-electron palladium catalysis alone. These platforms, pioneered by MacMillan and expanded by Molander, Doyle, and others, are now routinely deployed in pharmaceutical medicinal chemistry and are scaling towards manufacturing application. Electrochemically, the principle of electrocatalysis has reinvigorated first-row transition metal catalysis: nickel complexes driven by cathodic reduction at the electrode surface undergo Ni(0)/Ni(I)/Ni(II)/Ni(III) cycling that enables reductive cross-coupling of alkyl and aryl electrophiles without external chemical reductants, stoichiometric metals, or organometallic reagents. Manganese and cobalt complexes are finding application in electrochemically driven C-H functionalisation and electro-oxidative annulation reactions. Iron-catalysed electrochemical Kharasch addition and cobalt-mediated electrochemical hydration further illustrate how the electrochemical modulation of metal oxidation state unlocks mechanistic pathways that complement and extend the established repertoire of transition metal-catalysed transformations in sustainable pharmaceutical synthesis.

Our catalogue of transition metal complexes and associated reagents spans palladium precatalysts, phosphine-metal complexes, chiral rhodium and ruthenium hydrogenation catalysts, photoredox iridium and ruthenium complexes, and nickel and copper cross-coupling systems, to support drug discovery, process research, and pharmaceutical manufacturing across all stages of development.